Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10367341 | PMC |
| http://dx.doi.org/10.3389/fimmu.2023.1203531 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combined treatment with CDK4/6, CDK2, and CXCR1/2 inhibitors effectively halts the growth of BRAF wild-type melanoma tumors.
Front Oncol
August 2025
Tennessee Valley Healthcare System (TVHS) Department of Veterans Affairs, Nashville, TN, United States.
Introduction: Inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6) are approved for the treatment of locally advanced or metastatic breast cancer, but not for melanoma.
Methods: In this study, we evaluated the effectiveness of the CDK4/6 inhibitor, palbociclib, the CDK2 inhibitor, PF-07104091, the dual CXCR1 and CXCR2 (CXCR1/2) antagonist, SX-682, and the combination of these inhibitors for effective treatment of melanoma in preclinical models.
Results: Both palbociclib and SX-682 inhibited the growth of BRAF/NRAS B16-F10 and NRAS 1014 melanoma tumors and in both models, SX-682 created a more anti-tumor immune microenvironment.
Chimeric anti-HLA antibody receptor engineered human regulatory T cells suppress alloantigen-specific B cells from pre-sensitized transplant recipients.
Front Immunol
September 2025
Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC, United States.
Organ transplantation is a lifesaving procedure, with 50,000 transplants happening every year in the United States. However, many patients harbor antibodies and B cells directed against allogeneic human leukocyte antigen (HLA) molecules, notably HLA-A2, greatly decreasing their likelihood of receiving a compatible organ. Moreover, antibody-mediated rejection is a significant contributor to chronic transplant rejection.
View Article and Find Full Text PDFComparison of viral phenotype and inflammatory biomarker responses in acute HIV-1 subtype A and C infections.
Front Microbiol
August 2025
Emory Vaccine Center at Emory National Primate Research Center, Atlanta, GA, United States.
Introduction: HIV-1 subtype A and subtype C infections have different rates of clinical disease progression, with subtype C infected individuals in the IAVI Protocol C multisite acute infection cohort having a 60% faster CD4 loss compared to subtype A.
Methods: In order to investigate whether differences were due to the phenotype of the transmitted founder virus (TFV), or inflammatory cytokines and chemokines, known to drive pathogenesis, we PCR amplified, sequenced and constructed infectious molecular HIV-1 clones from the plasma of 30 acutely infected individuals in Rwanda and Zambia. We next compared the inflammatory plasma cytokine/chemokine profiles of individuals pre- and post-the estimated date of infection of 20 Rwandan individuals infected with subtype A and 34 Zambians infected with subtype C HIV-1.
Nanoengineered-based delivery systems to modulate CD4 T cell responses in cancer: emerging paradigms in cancer immunotherapy.
Front Pharmacol
August 2025
Department of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia.
Background: CD4 T-cells play a pivotal role in cancer immunology, functioning as both tumor-suppressing and tumor-promoting agents depending on their differentiation and cytokine profiles. Targeting CD4 T-cells with novel drug delivery systems, particularly nanoparticle-based formulations, offers a promising approach to enhancing antitumor immune responses while minimizing systemic toxicity.
Objective: This review aims to explore the immunological significance of CD4 T-cells in cancer and their modulation using novel drug delivery systems.
Identification of cellular factors associated with inflammation and neurodegeneration in multiple sclerosis.
Front Immunol
August 2025
Department of Immunology, Hospital Universitario Ramón y Cajal, Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), ISCIII, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
Background: Serum biomarkers as neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) enabled early identification of multiple sclerosis (MS) patients at risk of relapse-associated worsening (RAW) or progression independent of relapses (PIRA). However, the immunological mechanisms underlying these clinical phenotypes remain unclear.
Methods: We conducted a cross-sectional study including 117 MS patients and 84 healthy controls (HC).